Abstract
A retrospective case-control study of 12 patients positive forStenotrophomonas maltophilia and 24 age-sex-matched controls revealed that in the year prior to initial isolation, colonised patients spent more days in hospital and received more days of oral ciprofloxacin, intravenous anti-pseudomonal antibiotics, and nebulised aminoglycosides. They were also more likely to have grownPseudomonas aeruginosa at some time in the past, despite there being no difference in current chronic infection with this organism. The role of anti-pseudomonal antibiotics in promotingStenotrophomonas maltophilia colonisation in cystic fibrosis is discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ballestero S, Virseda I, Escobar H, Suarez L, Baquero F:Stenotrophomonas maltophilia in cystic fibrosis patients. European Journal of Clinical Microbiology & Infectious Diseases 1995, 14: 728–729.
Chatelut M, Dournes JL, Chabanon G, Marty N: Epidemiological typing ofStenotrophomonas (Xanthomonas) maltophilia by PCR. Journal of Clinical Microbiology 1995, 33: 912–914.
Hoiby N:Pseudomonas infection in cystic fibrosis. In: Dodge JA, Brock DJH, Widdicombe JH (ed): Cystic fibrosis — current topics: volume 1, Wiley, Chichester, UK, 1993, p. 251–268.
Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH: Nebulised colomycin for earlyPseudomonas aeruginosa colonisation in cystic fibrosis. Lancet 1985, i: 865.
Valerius NH, Koch C, Hoiby N: Prevention of chronicPseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991, 338: 725–726.
Jensen T, Pedersen SS, Hoiby N, Koch C, Flensburg EW: Use of antibiotics in cystic fibrosis. The Danish approach. Antibiotics and Chemotherapy 1989, 42: 237–246.
Khardori N, Elting L, Wong E, Schable B, Bodey GP: Nosocomial infections due toXanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Reviews of Infectious Diseases 1990, 12: 997–1003.
Lesco-Bornet M, Pierre J, Sarkis-Karam D, Lubera S, Bergogne-Berezin E: Susceptibility ofXanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro. Antimicrobial Agents and Chemotherapy 1992, 36: 669–671.
Spencer RC: The emergence of epidemic, multiple-antibiotic-resistantStenotrophomonas (Xanthomonas) maltophilia andBurkholderia (Pseudomonas) cepacia. Journal of Hospital Infection 1995, 30, Supplement: 453–464.
Vazquez C, Municio M, Corera M, Gaztelurrutia L, Sojo A, Vitoria JC: Early treatment ofPseudomonas aeruginosa colonisation in cystic fibrosis. Acta Paediatrica 1993, 82: 308–309.
Hutchinson GR, Parker S, Pryor JA, Duncan-Skingle F, Hoffman PN, Hodson ME, Kaufmann ME, Pitt TL: Home-use nebulisers: a potential primary source ofBurkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis. Journal of Clinical Microbiology 1996, 34: 584–587.
Gladman G, Connor PJ, Williams RF, David TJ: Controlled study ofPseudomonas cepacia andPseudomonas maltophilia in cystic fibrosis. Archives of Disease in Childhood 1992, 67: 192–195.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Denton, M., Todd, N.J. & Littlewood, J.M. Role of anti-pseudomonal antibiotics in the emergence ofStenotrophomonas maltophilia in cystic fibrosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 15, 402–405 (1996). https://doi.org/10.1007/BF01690098
Issue Date:
DOI: https://doi.org/10.1007/BF01690098